impaired in type 2 Cagrilintide Long-acting amylin analogue (engineered copy) Binds to amylin and calcitonin receptors Half-life: ~7 days Once-weekly subcutaneous injection Designed specifically for chronic weight management How Cagrilintide works in the body Cagrilintide exerts its effects by binding to amylin receptors specifically the calcitonin receptor in combination with receptor activity-modifying proteins (RAMP1 and RAMP3)
Reported human anecdotal effects include nausea, dizziness, and injection site reactions
Blood pressure reductions, improvements in lipid profiles (lower triglycerides, higher HDL), reductions in waist circumference, and decreases in inflammatory markers have been documented for both
Choose DSIP when you need a straightforward tool for probing deep-sleep physiology and stress-axis regulation
With your levels restored, you have more energy to move, your metabolism runs the way it should, and it becomes easier to stick with a healthy plan
You may experience mild soreness at the injection site or temporary flushing